Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Scientists uncover genetic code driving tumor formation and spread

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

9 Dec 2024

Beckman Coulter Life Sciences Accelerates Drug Discovery with Launch of Cydem VT Automated Clone Screening System

...

From Beckman Coulter Life Sciences - Flow Cytometry 3 Dec 2024

Concizumab shows promising results for hemophilia patients

For people with the bleeding disorder hemophilia, life can seem like one continuous state of alertness. If they accidentally cut their finger while chopping vegetables, they have to immediately administer the clotting factor protein that their body either lacks or does not produce enough of.

2 Dec 2024

Researchers discover new cause of cytokine storm in COVID-19

As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children's Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine discovered a novel cause of cytokine storm - the extreme inflammatory response associated with increased risk of death in COVID-19 infection.

2 Dec 2024

New injection treatment could be a game-changer for people with asthma and COPD

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

27 Nov 2024

Cetuximab performs better than durvalumab in treating head and neck cancers

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.

22 Nov 2024

Kyushu University team develops antibody to fight age-related muscle atrophy

We all age. And while humanity's life expectancy has increased dramatically in the modern era, we still struggle with the inevitable health issues our bodies face as we get up in the years.

19 Nov 2024

Early RSV vaccination in pregnancy provides best protection for newborns

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) - which typically causes mild, cold-like symptoms in most adults but can be deadly for infants - during weeks 32–36 of pregnancy.

11 Nov 2024

New approach reinvigorates exhausted T cells to improve tumor control

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells - which have lost their cancer-fighting oomph - consume this lactic acid, which further saps their energy, according to new research from the University of Pittsburgh and UPMC Hillman Cancer Center.

8 Nov 2024

Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial cell cycle progression.

8 Nov 2024

Virtual screening yields small molecules to enhance cancer immunotherapy

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

7 Nov 2024

Emerging therapies transform autoimmune hepatitis treatment approaches

Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure.

6 Nov 2024

Binghamton University joins groundbreaking $42.8 million inflammatory disease treatment project

Binghamton University will play a key role in a federal grant of up to $42.8 million to develop an implantable device that acts as a living pharmacy to treat inflammatory diseases.

5 Nov 2024

Grant awarded to build a portable PET scanner for early Alzheimer's detection

Weill Cornell Medicine researchers have received a five-year $6.2 million grant from the National Institute on Aging, part of the National Institutes of Health, to build a portable, high-resolution Positron Emission Tomography (PET) scanner that can detect the earliest stages of Alzheimer's disease.

4 Nov 2024

Critical protein linked to spillover potential of animal viruses

Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses.

1 Nov 2024

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial.

27 Oct 2024